Business Wire

SBC Medical Group Acquires MB Career Lounge: “JUN CLINIC” Joins the Group, Strengthening Competitive Position in a Growing Market

17.7.2025 14:00:00 CEST | Business Wire | Press Release

Share

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global franchise and provider of services for aesthetic clinics, announced that, on July 17, 2025, it acquired MB career lounge, Co., Ltd. (“MB career lounge”), a privately-held provider of management support services for medical institutions, specializing in consulting, training, and human resources solutions in Japan, through a share purchase transaction for cash consideration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717637525/en/

JUN CLINIC

Through this transaction, JUN CLINIC, operated by Medical Corporation Misakikai and supported by MB career lounge, will join SBC Medical’s clinic network, contributing to portfolio diversification and is expected to enhance revenue stability.

“The surging demand for personalized aesthetic solutions, particularly 'Customized Laser Treatment,' underscores a rapidly expanding market. JUN CLINIC's proven success in diverse environments, from the developing regional market of Nagano to the highly competitive urban centers of Ginza and Shirokane, demonstrates a robust and easily scalable business model poised for nationwide expansion. By combining our strengths with MB career lounge and JUN CLINIC, we will strengthen our portfolio of aesthetic dermatology and plastic surgery services, enhancing our ability to serve our customers more effectively and further positioning the Company to capitalize on the growing demand for high-quality aesthetic medical services,” said Yoshiyuki Aikawa, Founder and Chief Executive Officer of SBC Medical. “This acquisition marks another important step in our growth strategy, accelerating regional expansion, diversifying service offerings, and reinforcing our commitment to driving long-term shareholder value. We look forward to welcoming the MB career lounge and JUN CLINIC team and working together to drive continued success.”

Japan’s aesthetic medicine market reached ¥631 billion in 2024, representing year-over-year growth of 6.2%, and is expected to continue its steady expansion.* Against this backdrop, SBC Medical is pleased to welcome JUN CLINIC—an established provider of both aesthetic dermatology and plastic surgery services—into its growing clinic network.

JUN CLINIC is a network of clinics across multiple locations, including Shirokane, Ginza, Tama Plaza, Yokohama, and Nagano, serving a diverse customer base across both metropolitan and regional areas. Renowned for its personalized treatment approach, the clinic offers a comprehensive suite of services including laser therapies, injectables, and thread lifts, all tailored to individual skin conditions and administered under the supervision of a board-certified dermatologist.

This acquisition enables SBC Medical to accelerate regional expansion, broaden its customer base and strengthen its business model by reducing reliance on any single procedure or geography. With JUN CLINIC’s long-standing reputation and stable revenue base, the acquisition is expected to enhance SBC Medical’s financial performance. Looking ahead, SBC Medical will continue to pursue strategic acquisitions and partnerships with high-quality medical institutions to support long-term growth and drive greater corporate value within the healthcare industry.

The addition of this sophisticated treatment platform aligns with SBC Medical's strategy of diversifying its service offerings and expanding its portfolio to embrace the significant trend of personalized medicine. The global demand for customized, non-invasive aesthetic solutions has the potential to achieve meaningful and durable growth. SBC Medical endeavors to capture this high-value market segment, including through integration of JUN CLINIC's proven model and its team of highly skilled professionals—validated by their role as a certified facility for the prestigious Customized Treatment Study Group.

(*Source: Yano Research Institute Ltd., “Survey on Japan’s Aesthetic Medicine Market 2025”)

About MB career lounge, Co., Ltd.

MB career lounge, Co., Ltd. is a consulting firm specializing in the aesthetic medical industry. MB career lounge offers a wide range of training and networking programs designed to enhance the knowledge, skills, and career development of doctors, nurses, and clinic managers. In addition to educational initiatives, MB career lounge provides comprehensive consulting services, including support for clinic startups, marketing strategies, operational optimization, management structure development, and selection and implementation of aesthetic medical devices. MB career lounge also provides management support for JUN CLINIC, operated by the medical corporation Misakikai. MB career lounge’s mission is to help clinics solve management challenges, achieve sustainable growth, and build trusted practices that patients choose. https://mbcareer.jp/ (Japanese only)

Transaction Overview

Transaction Type: Share acquisition with cash consideration
Closing Date: July 17, 2025
Consolidation Date: Q3 2025
Funding Source: Bank loan

About SBC Medical

SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit https://sbc-holdings.com/

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s acquisition of MB career lounge, product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250717637525/en/

Contacts

SBC Medical Group Holdings Incorporated (Asia)
Hikaru Fukui / Head of Investor Relations
E-mail: ir@sbc-holdings.com
Akiko Wakiyama/ Head of Public Relations
E-mail: pr@sbc-holdings.com

ICR LLC (In the US)
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye